ArticleBritish journal of cancer2001
Magnetic resonance detects changes in phosphocholine associated with Ras activation and inhibition in NIH 3T3 cells.
Article in British journal of cancer, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 77 citations in OpenAlex.
- Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy.BMC cancer · 2012Trial
- A New Light-Sensor System Affecting Cancer Cell Fate.Biomaterials research · 2025Article
- Imaging biomarkers of TERT or GABPB1 silencing in TERT-positive glioblastoma.Neuro-oncology · 2022Article
- MR-detectable metabolic biomarkers of response to mutant IDH inhibition in low-grade glioma.Theranostics · 2020Article
- The relevance of tyrosine kinase inhibitors for global metabolic pathways in cancer.Molecular cancer · 2018Review
- Breast Tissue Metabolism by Magnetic Resonance Spectroscopy.Metabolites · 2017Review
- Near infrared fluorescent imaging of choline kinase alpha expression and inhibition in breast tumors.Oncotarget · 2017Article
- Article
- Metabolite profiling in retinoblastoma identifies novel clinicopathological subgroups.British journal of cancer · 2015Article
- Magnetic resonance spectroscopy for detection of choline kinase inhibition in the treatment of brain tumors.Molecular cancer therapeutics · 2015Article
- Metabolic reprogramming in mutant IDH1 glioma cells.PloS one · 2015Article
- MR-detectable metabolic consequences of mitogen-activated protein kinase kinase (MEK) inhibition.NMR in biomedicine · 2014Article
- Silencing of the glycerophosphocholine phosphodiesterase GDPD5 alters the phospholipid metabolite profile in a breast cancer model in vivo as monitored by (31) P MRS.NMR in biomedicine · 2014Article
- Monitoring response to cytostatic cisplatin in a HER2(+) ovary cancer model by MRI and in vitro and in vivo MR spectroscopy.British journal of cancer · 2014Article
- Noninvasive phosphorus magnetic resonance spectroscopic imaging predicts outcome to first-line chemotherapy in newly diagnosed patients with diffuse large B-cell lymphoma.Academic radiology · 2013Article
- Treatment with the MEK inhibitor U0126 induces decreased hyperpolarized pyruvate to lactate conversion in breast, but not prostate, cancer cells.NMR in biomedicine · 2013Article
- HDAC inhibition induces increased choline uptake and elevated phosphocholine levels in MCF7 breast cancer cells.PloS one · 2013Article
- Metabolic consequences of treatment with AKT inhibitor perifosine in breast cancer cells.NMR in biomedicine · 2012Article
- Choline metabolism in malignant transformation.Nature reviews. Cancer · 2011Review
- MRS and MRSI guidance in molecular medicine: targeting and monitoring of choline and glucose metabolism in cancer.NMR in biomedicine · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ras is frequently mutated in cancer, and novel therapies are being developed to target Ras signalling. To identify non-invasive surrogate markers of Ras activation and inhibition, we used(31)P magnetic resonance spectroscopy (MRS) and investigated NIH 3T3 cells compared to a mutant ras transfected counterpart. The MR spectra indicated that phosphocholine (PC) levels increased significantly from 3 +/- 2 fmol cell(-1)in NIH 3T3 cells to 13 +/- 4 fmol cell(-1)in the transfected cells. The PC/NTP ratio increased significantly from 0.3 +/- 0.1 to 0.7 +/- 0.3. This could not be explained by either a faster proliferation rate or by alterations in cell cycle distribution. Both cell lines were treated with simvastatin, 17-AAG and R115777, agents which inhibit Ras signalling. Cell proliferation was inhibited in both cell lines. The spectrum of NIH 3T3 cells was not affected by treatment. In contrast, in the ras transfected cells growth inhibition was associated with an average 35 +/- 5% drop in PC levels and a comparable drop in PC/NTP. Thus the MRS visible increase in phosphocholine is associated with Ras activation, and response to treatment is associated with partial reversal of phosphocholine increase in ras transfected cells. MRS might therefore be a useful tool in detecting Ras activation and its inhibition following targeted therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.